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Summary Using immunohistochemistry and the monoclonal antibody C219 we have investigated P-
glycoprotein expression in 26 locally advanced breast cancers. Twenty four patients had received four cycles of
chemotherapy (mitozantrone, mitomycin-C and methotrexate) prior to mastectomy; two received tamoxifen.
Twelve tumours exhibited an objective response to the chemotherapy.
A background pattern of isolated weakly positive (1+) stromal staining (myofibroblast) was observed in
seven tumours, two of which had been treated by tamoxifen alone. Two of the tumours treated by induction
chemotherapy showed positive staining (1+) within a very small number of isolated tumour cells (maximum
of three) and macrophages. The significance of this staining is not clear although C219 may simply be cross
reacting with myosin. We have failed to demonstrate a clear clinical utility for C219 in breast cancer, partic-
ularly regarding the identification of patients in whom MDR chemotherapy be avoided once metastases
develop.
Acquired cytotoxic drug resistance is one of the major
obstacles to effective cancer chemotherapy, no more so than
when treating disseminated breast cancer. Strategies to over-
come it, such as the use of alternative drug combinations and
high dose chemotherapy have met with limited success. The
pattern of resistance is often not limited to the primary
treatment but includes cross resistance to other structurally
unrelated agents, agents to which the tumour was never
exposed.
An understanding of the molecular mechanisms underlying
the development of drug resistance is requisite in devising
therapeutic strategies to circumvent or avoid the emergence
of refractory tumours. Although the mechanisms are poorly
understood a multidrug resistance phenotype (MDR) has
been characterised in a colchicine-resistant, Chinese hamster-
lung cell line and P388 leukaemia cells (Biedler & Riehm,
1970). These cells show cross resistance to several drugs
including actinomycin-D, vinblastine (Biedler & Riehm,
1970), vinca alkaloids, anthracyclines and etoposide (Seeber
et al., 1982). MDR cell lines may also show cross resistance
to mitomycin-C (Dorr et al., 1987; Biedler & Riehm, 1970)
and mitozantrone (Morrow & Cowan, 1988; Schneider et al.,
1989). Although relative resistance to these drugs may vary
quantitatively between different MDR cell lines patterns of
cross resistance are qualitatively uniform regardless of the
selecting drug (Morrow & Cowan, 1988; Schneider et al.,
1989). Although relative resistance to these drugs may vary
quantitatively between different MDR cell lines patterns of
cross resistance are qualitatively uniform regardless of the
selecting drug (Morrow & Cowan, 1988). Resistance may
relate to a decrease in intracellular accumulation of cytotoxic
drugs, a consistent feature being the over-expression of a
plasma membrane glycoprotein termed P-glycoprotein which
is thought to function as an efflux pump (Juliano & Ling,
1976). The MDR phenotype is also associated with increased
expression of the MDR gene, mdr-I (Roninson et al., 1984)
which encodes for P-glycoprotein; P-glycoprotein expression
correlates with the degree of drug resistance (Kartner et al.,
1983).
Most of our information regarding the mechanism of mul-
tidrug resistance is derived from in vitro studies of cells
selected for extremely high levels of drug resistance unlikely
to be encountered clinically. It is not known if similar
mechanisms are responsible for in vivo drug resistance. We
present a series of patients with stage III breast cancer
treated by a course of 'multidrug resistance related
chemotherapy', radical surgery and postoperative
radiotherapy. P-glycoprotein expression within the tumour
cells of the mastectomy specimens was investigated using the
commercially available murine monoclonal antibody C219
(CIS (UK), High Wycombe). We hoped to be able to use the
information in planning chemotherapy regimens in the event
of systemic relapse.
Patients and methods
Twenty four women with locally advanced primary breast
cancer characterised by one or more of the following
features: > 5 cm on clinical measurement, fixation to under-
lying chest wall, gross nodal involvement, satellite skin
nodules, skin infiltration/ulceration > than the diameter of
the tumour in the absence of metastases have been treated by
a combination of chemotherapy, radical surgery and radio-
therapy. Chemotherapy comprised mitomycin-C 8 mg m-2
every 6 weeks, mitozantrone 8 mgmi-2 every 3 weeks and
methotrexate 30 mg mI-2 every 3 weeks, administered for four
courses (i.e., 9 weeks from day one). Response was assessed 3
weeks after the last injection using standard UICC criteria.
Surgery was performed within 4 weeks of completing the
chemotherapy.
Tumours specimens were obtained at the time of surgery
and immediately snap-frozen in liquid nitrogen before
storage at
- 70°C. Two further tumour specimens were
obtained from patients whose disease progressed on tamoxi-
fen.
Immunohistochemistry
Cryostat sections (6 ftm) of the tumour samples were
prepared, allowed to air dry overnight before fixation in fresh
cold acetone at -20°C. The sections were then washed in
Tris Buffered Saline (TBS). The monoclonal antibody to
P-glycoprotein, C219 (Centocor, Malvern, PA, USA) was
applied to the sections for 44 minutes at a dilution of
20iLg ml-'; the diluent was 1:5 normal swine serum (NSS) in
TBS. A concentration of 20lAg ml-' is not excessive and was
chosen to increase the sensitivity of the method to ensure
that no low levels of labelling were missed. Specimens were
then washed in TBS, 3 changes of 2-3 min each. The peroxi-
dase conjugated rabbit anti-mouse immunoglobulin (Dako,
High Wycombe Bucks, UK) at a 1:60 dilution was applied
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for 30 min, again using NSS/TBS as the diluent. Specimens
were again washed. The colour reaction was produced using
DAB (diaminobenzidine) solution (5 mg in 10 ml pH 7.6 Tris
buffer) mixed with 5 mg of Imidazole, adding 80 tlI of 3%
hydrogen peroxide immediately before use. After washing in
deionised water, the sections were left to stand for 5 min in
0.5% copper sulphate solution in 0.85% NaCl to intensify
the colour. The preparations were counterstained with
Mayer's haematoxylin before mounting in XAM.
Negative controls for each sample were performed as
above but with omission of the C219 antibody. Two positive
control systems were used: P-glycoCheckT control slides
employing the human acute lymphoblastic leukaemia cell line
CEM-VLB1, (Centocor Diagnostics, Malvern, PA, USA)
and the doxorubicin hydrochloride (dox) resistant lung car-
cinoma cell line EMT6/AR/1.0 provided as a donation from
Dr P. Twentyman, Addenbrooks Hospital, Cambridge. Test
and control slides were stained simultaneoulsy to control for
variations in staining technique and both positive controls
showed intense labelling. All slides were evaluated by one of
the authors (IOE) without knowledge of the clinical data.
After initial review, stromal and tumour cells were scored
separately, all on a four point basis: 0 = no staining,
1 + = weak staining, 2+ = moderate staining, 3+ = strong
staining.
Results
The overall objective response rate to the neo-adjuvant
chemotherapy was 50%; all were partial. A further seven
patients (29%) had stable disease whilst the remainder pro-
gressed. Three of the seven patients whose disease progressed
whilst receiving the chemotherapy have since developed
systemic spread (median metastases free interval 13 months).
Metastases have also developed in four of the seven patients
classified as stable disease. Only two patients have shown
response in their metastases to dox containing regimens.
None of the 26 primary tumours studied has stained
clearly and convincingly positive for P-glycoprotein; small
amounts ofweak stromal staining (1 +) were observed in two
tumours treated by tamoxifen. Four tumours treated by
chemotherapy showed a similar pattern of staining including
a positive reaction (1+) within normal duct epithelium in
two. Stromal staining (2+) was observed in a further tumour
that had shown static disease (Figure 1); staining (1+) was
also observed in isolated tumour cells (max. of three) and
several clumps of macrophages. None of the seven tumours
which went on to metastasise exhibited any positive staining.
Strong (3+) P-glycoprotein immunoreactivity was readily
detectable in the two positive control cell lines (Figures 2 and
3). No staining occured in the negative controls (Figures 4
and 5).
Discussion
Whilst there are too little data to support a definite role for
P-glycoprotein in drug resistance in vivo (Anonymous, 1989)
several important observations have been made. Immuno-
histochemical studies have shown high expression in organs
such as the liver, kidney, colon and adrenal gland (Fojo et
al., 1987; Thiebaut et al., 1987) specifically localised on the
apical or secretory surface. It is thought that this protein may
play a part in the normal secretion of metabolites or cellular
toxins. It is interesting that tumours derived from these
tissues are typically resistant to chemotherapy. Other investi-
gators have suggested a relationship between P-glycoprotein
expression in sarcomas (Gerlach et al., 1987), leukaemia (Ma
et al., 1987) ovarian carcinoma (Bell et al., 1985) phaechro-
mocytoma (Fojo et al., 1987) and evolving clinical resist-
ance.
P-glycoprotein has been detected in breast cancer using the
MRK 16 monoclonal antibody to P-170 (Sugawara et al.,
1988). Using the cDNA probe however, Merkel et al. (1988)
failed to find a single case of over-expression of mdr-1 RNA
amongst 248 breast carcinomas; seven of these patients had
received prior MDR related chemotherapy and 22 none-
related cytotoxics. High levels were obtained in positive con-
trols. RNA analysis of 95 tumours from the same series also
failed to identify the MDR phenotype, even in patients who
had received adriamycin. Similar findings have been noted by
other workers (Schneider et al., 1989). Using similar methods
other groups (Goldstein et al., 1989) have reported over-
expression of mdr-1 RNA in nine of 57 breast cancers, two
of which had received non-specified treatments.
Figure 1 Photomicrograph of tumour showing positive C219 staining within stromal cells (myofibroblasts) and macrophages.P-GLYCOPROTEIN EXPRESSION IN LOCALLY ADVANCED BREAST CANCER 539
Figure 2 Positive staining for C219 in the P-glycoCheck" control slide.
Figure 3 Positive staining for C219 and the EMT6/AR/1.0 cell line.
Using the monoclonal antibody C219, Schneider et al.
(1989) reported finding minimal P-glycoprotein activity in
2/12 untreated breast cancers. This was in contrast to a
positive finding in 3/7 patients receiving MDR related
chemotherapy; 3/4 patients treated by known non-MDR
related substances also showed reactivity in isolated tumour
cells. These workers were unable to explain the above
differences, suggesting that the isolated positive cells 'be con-
sidered negative'. Figures la2: case no. 22 (Schneider et al.,
1989) pertaining to show a positive reaction in the tumour
cells to P-glycoprotein appears on reflection to only represent
background stromal staining; the tumour cells shown in the
photomicrograph stain negative for C219. These findings
suggest that P-glycoprotein expression in breast cancer is not
a common event and has been attributed to glycoprotein's
heterogeneity of expression (Keith et al., 1990).
More frequent levels of expression have been recently
reported. C219 staining was observed (Ro et al., 1990) in 20540 A.R. DIXON
Figure 4 Negative staining for the P-glycoCheckT control slide in the absence of C219.
Figure 5 Negative staining of the EMT6/AR/1.0 cell line in the absence of C219.
of 48 tumours treated by three cycles of induction
chemotherapy (doxorubicin, vincristine cyclophosphamide
and prednisolone), response correlating inversely with P-
glycoprotein expression. Verelle et al., 1991 found that the
majority (17 of 20) of untreated locally advanced breast
cancer specimens stained clearly positive using the C494
monoclonal antibody and that highly positive staining was
related to both resistance to the MDR regimen and a shorter
period of progression-free survival. C494 binds to an internal
P-glycoprotein epitope distinct from those recognised by the
C219 and MRK 16 monoclonal antibodies (Kartner et al.,
1985).
Using the same C219 monoclonal antibody we have been
unable to clearly identify P-glycoprotein expression within
breast tumour cells treated by induction MDR related
chemotherapy. Weakly positive staining was found within the
surrounding stroma of two tumours treated by tamoxifen
and four by MDR related chemotherapy. A more 'intense'P-GLYCOPROTEIN EXPRESSION IN LOCALLY ADVANCED BREAST CANCER 541
pattern of stromal staining associated with isolated positive
tumour cells and macrophages was observed in one patient.
Similar stromal staining has been reported by one other
group (Wishart et al., 1990). No staining was observed in any
of the tumours which were to metastasise early, including the
five which later proved resistant to dox containing regimens.
The significance of these findings is not clear, particularly as
the immunohistochemical method used is a highly sensitive
technique and positive and negative controls stained appro-
priately. Whilst accepting that the MMM regimen is only
tenuously related to multidrug resistance, weekly positive
staining was observed in stromal cells suggesting protein
expression. P-glycoprotein expression may take longer than
four months to develop within tumour cells and require more
than four cycles of MMM cytotoxics. However, resistance of
the MDR type has been demonstrated experimentally in cell
lines that do not over-express P-glycoprotein (Danks et al.,
1987). Recent evidence has suggested that the C219 mono-
clonal antibody may cross react with the heavy chain of
myosin (Thiebaut et al., 1989) in skeletal and cardiac muscle.
Although this may be the case here, recent reports (Bradley
et al., 1990) suggest that C219 is more likely to be detecting
another isoform of P-glycoprotein, perhaps class' III.
Whilst P-glycoprotein expression is sufficient to confer
resistance in vitro the development of complex phenotypic
changes in these cells, as well as the phenomenon of non
P-glycoprotein expression in resistant cell lines suggests that
the picture is highly complex and that other mechanisms are
involved. Unlike other groups (Ro et al., 1990; Verelle et al.,
1991) we have been unable to demonstrate any clear prog-
nostic utility within this small group of patients in using
C219 to examine for P-glycoprotein expression, particularly
with regard to identifying tumours where MDR
chemotherapy e.g. dox be avoided once metastases
develop.
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